Top Price Market
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Top Price Market

Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Saskatchewan Research Council Achieves Commercial Production at Rare Earths Facility
next post
Newsom’s deepfake election laws are already being challenged in federal court

You may also like

Galan Lithium

Toro Energy

IperionX Announces US$47.1 Million Titanium Deal with US...

Lancaster Resources Receives BLM Drilling Approval for Alkali Flat...

11 Canadian Cryptocurrency ETFs

Leinster South Update

ChemX Materials

FPX Nickel Announces Approval of Normal Course Issuer...

Crypto Market Recap: Trump Tariff Turmoil

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Massachusetts suspect charged with attempting to assassinate a Cabinet nominee

    • Pakistan says it has struck military targets inside India in series of new attacks

    • Rodrigo Duterte is being held at The Hague. Next week he might be elected mayor of his hometown

    • Buffett Hands Over Reins, What’s Next for Berkshire’s Capital Strategy?

    • Triumph Gold Updates Shareholders on Operations, Engages Market Maker, and Grants Options

    Categories

    • Business (1,632)
    • Investing (4,787)
    • Politics (7,557)
    • Uncategorized (2)
    • World (6,139)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 toppricemarket.com | All Rights Reserved


    Back To Top